{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:16:16Z","timestamp":1783005376362,"version":"3.54.5"},"reference-count":27,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Irregular menses and chronic anovulation are key components of Polyendocrine Metabolic Ovarian Syndrome (PMOS), but available treatments generally only mask the clinical problem, which presents itself again when the drugs are stopped. Because reduction of body weight in these patients is often associated with improvement of menstrual cycles, we evaluated the effects of treatment with semaglutide, a GLP-1 agonist that has emerged as an effective treatment for obesity. Methods: A total of 96 women with PMOS and body mass index (BMI) &gt; 25 kg\/m2 completed a six-month treatment protocol with semaglutide using an individualized dose-escalation regimen. Body weight, fasting glucose, insulin levels, insulin resistance (HOMA-IR), and ovulatory function were assessed before and after treatment. Results: After six months of treatment, mean body weight decreased significantly (\u221211.3 \u00b1 5%, p &lt; 0.01). Before treatment, 83% of PMOS patients presented with oligomenorrhea and anovulatory cycles. Following treatment, ovulatory cycles were observed in 52.5% of previously anovulatory women. The results were particularly good in overweight patients, with almost 95% of these PMOS patients achieving menstrual cycle normalization and ovulation, but also in patients with mild obesity. Results were less favorable in PMOS patients with moderate or severe obesity, but 25% of these patients achieved menstrual ovulatory cycle normalization when treated with semaglutide. Conclusions: This study represents an important therapeutic advancement, suggesting that women with PMOS and excessive body weight should be considered for treatment with GLP-1 receptor agonists before proceeding to therapies specifically aimed at inducing normal cycles and ovulation.<\/jats:p>","DOI":"10.3390\/jcm15135165","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:43:14Z","timestamp":1783003394000},"page":"5165","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-7610","authenticated-orcid":false,"given":"Enrico","family":"Carmina","sequence":"first","affiliation":[{"name":"School of Medicine, University of Palermo, 90139 Palermo, Italy"},{"name":"Endocrinology Unit, FB Medical Center, 20121 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Alba","family":"Longo","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, FB Medical Center, 20121 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rotterdam ESHRE-ASRM Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum. Reprod., 19, 41\u201347.","DOI":"10.1093\/humrep\/deh098"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.fertnstert.2010.02.014","article-title":"Clinical and endocrine characteristics of the main PCOS phenotypes","volume":"94","author":"Guastella","year":"2010","journal-title":"Fertil. Steril."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria","volume":"27","author":"Yildiz","year":"2012","journal-title":"Hum. Reprod."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jcem.84.6.5803","article-title":"Polycystic Ovary Syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women","volume":"84","author":"Carmina","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0140-6736(26)00717-8","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process","volume":"407","author":"Teede","year":"2026","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1210\/jc.2004-2279","article-title":"Phenotypic Variation in Hyperandrogenic Women Influences the Findings of Abnormal Metabolic and Cardiovascular Risk Parameters","volume":"90","author":"Carmina","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.fertnstert.2007.01.032","article-title":"Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria","volume":"88","author":"Shroff","year":"2007","journal-title":"Fertil. Steril."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/cen.14063","article-title":"Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily","volume":"91","author":"Carmina","year":"2019","journal-title":"Clin. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Carmina, E., and Lobo, R.A. (2022). Comparing Lean and Obese PCOS in Different PCOS Phenotypes: Evidence That the Body Weight Is More Important than the Rotterdam Phenotype in Influencing the Metabolic Status. Diagnostics, 12.","DOI":"10.3390\/diagnostics12102313"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with Polycystic Ovary Syndrome: A consensus statement of the Androgen Excess and PCOS (AE-PCOS) Society","volume":"85","author":"Wild","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1210\/jc.2013-2375","article-title":"The lifecycle of PCOS","volume":"98","author":"Welt","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmv025","article-title":"Metformin and lifestyle modification in polycystic ovary syndrome: Systematic review and meta-analysis","volume":"21","author":"Naderpoor","year":"2015","journal-title":"Hum. Reprod. Update"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.ijo.0800818","article-title":"Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men","volume":"23","author":"Barkeling","year":"1999","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: Physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management","volume":"70","author":"Singh","year":"2022","journal-title":"J. Investig. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/jcpt.13574","article-title":"Clinical review of subcutaneous semaglutide for obesity","volume":"47","author":"Phillips","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e13717","DOI":"10.1111\/obr.13717","article-title":"Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety","volume":"25","author":"Sandsdal","year":"2024","journal-title":"Obes. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Carmina, E., and Longo, R.A. (2023). Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185921"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis","volume":"14","author":"Ayoub","year":"2025","journal-title":"J. Clin. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1530\/eje.0.1390421","article-title":"Prevalence of idiopathic hirsutism","volume":"139","author":"Carmina","year":"1998","journal-title":"Eur. J. Endocrinol."},{"key":"ref_26","unstructured":"Strauss, J.F., Barbieri, R.L., Dokras, A., Williams, C.J., and Williams, Z. (2023). Evaluation of hormonal status. Yen & Jaffe\u2019s Reproductive Endocrinology, Elsevier. [10th ed.]."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 Receptor Agonists","volume":"394","author":"Rosen","year":"2026","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5165\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:46:04Z","timestamp":1783003564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":27,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135165"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135165","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}